In the ABCSG R02 trial we previously demonstrated that downstaging of the N-level and particularly the achievement of lymph node negativity after neoadjuvant RCT with capecitabine and oxaliplatin (ABCSG R02-Study) exerts a statistically significant influence on 5-year OS and DFS in this patient population ( 23 ), whereas downstaging at the T-level showed no statistically significant influence on OS and only a borderline significance in DFS.
← all excerpts
Prediction of survival after neoadjuvant therapy in locally advanced rectal cancer - a retrospective analysis.
1
—
—